Levosalbutamol 0.63mg + Ipratropium 500mcg Respule in PCD pharma franchise in Hyderabad

Levosalbutamol 0.63mg + Ipratropium 500mcg Respule in pharmaceutical manufacturing company in Mumbai

Levosalbutamol 0.63mg + Ipratropium 500mcg Respule in respiratory care pharma franchise in Pune

Levosalbutamol 0.63mg + Ipratropium 500mcg Respule in pharma suppliers in Delhi

Levosalbutamol 0.63mg + Ipratropium 500mcg Respule in pharma export companies in Kolkata
Levosalbutamol 0.63mg + Ipratropium 500mcg Respule in pharma franchise opportunities in Bengaluru

Home/Products /levosalbutamol-0-point-63-mg-ipratropium-500-mcg-respule

Critsal IT Respule

Composition : Levosalbutamol 0.63 mg + Ipratropium 500 mcg respule

Dosage Form : Respule

Packaging Type : Pack

Packaging : 4x5x2.5 ml

Price : ₹250/-

This respule contains Levosalbutamol 0.63 mg and Ipratropium Bromide 500 mcg, a combination of a selective β2-agonist and an anticholinergic bronchodilator. It is formulated for nebulization and used to relieve bronchospasm in patients with chronic obstructive pulmonary disease (COPD) and asthma. Levosalbutamol provides quick bronchodilation, while Ipratropium enhances the bronchodilatory effect by inhibiting vagally mediated reflexes.

Read More

About the Product

This respule contains Levosalbutamol 0.63 mg and Ipratropium Bromide 500 mcg, a combination of a selective β2-agonist and an anticholinergic bronchodilator. It is formulated for nebulization and used to relieve bronchospasm in patients with chronic obstructive pulmonary disease (COPD) and asthma. Levosalbutamol provides quick bronchodilation, while Ipratropium enhances the bronchodilatory effect by inhibiting vagally mediated reflexes.

Patients may experience dry mouth, cough, nervousness, tremor, headache, or dizziness. Rarely, palpitations, urinary retention, or eye irritation (if nebulized mist reaches the eyes) may occur.

Indicated for the treatment of reversible bronchospasm associated with COPD, chronic bronchitis, emphysema, and moderate to severe asthma, especially in patients who require more than one bronchodilator.

Use under medical supervision. For inhalation only via nebulizer. Avoid contact with eyes. Not recommended for mixing with other nebulizer medications unless prescribed. Caution is advised in patients with glaucoma, prostatic hypertrophy, or cardiovascular disease.

Store at room temperature (15-30°C), away from direct sunlight and moisture. Keep out of reach of children.

Get in Touch

Regulatory Compliance & Professional Verification

This catalog is a digital representation of the Cafoli Lifecare portfolio and is intended for use by authorized pharmaceutical distributors and PCD franchise partners.

  • No Consumer Sale: We do not entertain retail inquiries or direct sales to patients.
  • Information Accuracy: While we strive for accuracy, product availability, packaging, and regulatory status may change based on CDSCO guidelines and state-specific drug laws.
  • Medical Advice: Patients are strictly advised not to self-medicate or use this information for treatment. Always consult a qualified medical practitioner.
  • Licensing: All business associations are subject to the submission of valid GST and Drug License (DL) documentation.

Strategic Advisory

Ms. Shiwani Dhiman

VP-Strategic Outreach & Engagement

Ms. Shiwani specializes in market outreach and strategic partnership orchestration for entrepreneurs building scalable PCD Pharma Franchise models.

View Professional Profile

Start Your Journey

Partner With Cafoli

Ready to Dominate your territory with a Monopoly-Based PCD Franchise? Join our rapidly growing network of successful franchise partners and turn your ambitions into reality. Limited Territories Available — Don’t Miss Out!

Quick Navigation